Wednesday, July 26, 2017

Review - HCC Risk and Direct-Acting Antivirals

Medscape Coverage from
Digestive Disease Week (DDW) 2017 

With Hepatitis C Virus on the Run, Meet the New Challenge: Hepatocellular Carcinoma
William F. Balistreri
July 26, 2017
Significant advances in the clinical practice of hepatology were addressed during this year's Digestive Disease Week. This review focuses on the concerns related to the apparent increase in the incidence of hepatocellular carcinoma (HCC).

HCC Risk and Direct-Acting Antivirals
The advent of direct-acting antivirals (DAAs) has clearly brought good news, as it may now be possible to achieve a sustained virologic response (SVR)—a "virologic cure"—in the majority of patients with chronic hepatitis C virus (HCV). However, emerging data suggest that the risk for HCC may persist or even be increased by DAA administration. This concern was addressed by two studies
Continue reading....

Free registration may be required

On This Blog
Liver Cancer After Treatment For Hepatitis C
Sift through a collection of current articles investigating the possible risk of developing liver cancer (hepatocellular carcinoma, or HCC) during and after direct-acting antiviral therapy in patients with hepatitis C.

No comments:

Post a Comment